← Back to Library
Updated Guidelines for Treatment Initiation of Restless Legs Syndrome (2025)
⚠️ Major change: Risk of augmentation with long-term dopamine agonists — many former first-line treatments are now against recommendation.
2012 vs 2025 Recommendations
2012 Guidelines
| Recommendation | Agents |
|---|
| Strong For | Pramipexole, Ropinirole |
| Conditional For | Levodopa, Gabapentin enacarbil |
| Optional | Gabapentin, Pregabalin, Carbamazepine, Supplemental iron |
2025 Guidelines — Major Changes
| Recommendation | Agents |
|---|
| Strong For | Gabapentin, Gabapentin enacarbil, Pregabalin, IV Ferric carboxymaltose |
| Conditional For | Peroneal nerve stimulation (NEW), Opioids, Oral iron, Other IV iron, Dipyridamole |
| Conditional Against | Levodopa, Pramipexole, Ropinirole, Transdermal rotigotine, Carbamazepine, Clonazepam |
Iron Management
Lab Protocol
- Draw iron studies fasting
- Avoid red meat and iron supplements the day before
Treatment Thresholds
| Condition | Treatment |
|---|
| Ferritin < 75 mcg OR Transferrin saturation < 20% | Oral iron + Vitamin C |
| Ferritin 75–300 mcg AND Transferrin saturation < 45% | IV iron (preferably ferric carboxymaltose)
Repeat iron panel at 8 and 16 weeks after infusion |
Consider IV iron if:
- No response to oral iron
- Need rapid response
- Cannot absorb oral iron
Key Takeaways
- Dopamine agonists (pramipexole, ropinirole) downgraded — augmentation risk
- Gabapentinoids (gabapentin, pregabalin) now first-line
- IV ferric carboxymaltose is strongly recommended
- Iron repletion is central to management